A recent survey commissioned by the OSUCCC—James found that, while most U.S. adults identify family history (DNA-based risk passed down through families) as a risk factor for colorectal cancer, other factors such as alcohol use, lack of physical activity, and an American diet that is high in fat and processed foods were less known.
Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.
